| 货号 | MAB1609-SP |
| 别名 | B cell stimulatory factor-2; B-cell differentiation factor; BSF-2; BSF2CTL differentiation factor; CDF; HGFHSFIFNB2Hybridoma growth factor; IFN-beta 2; IFN-beta-2; IL-6B-cell stimulatory factor 2; Interferon beta-2; interleukin 6 (interferon, beta 2); interleukin BSF-2; interleukin-6; MGI-2A | 全称 | Interleukin 6 |
| 反应种属 | Canine |
| 应用 | Neutralization |
| 目标/特异性 | Detects canine IL-6 in direct ELISAs. In direct ELISAs, no cross‑reactivity with recombinant mouse (rm) Cardiotrophin-1, recombinant human (rh) CLC, recombinant rat (rr) CNTF, recombinant cotton rat IL-6, recombinant equine IL-6, rhIL-6, recombinant porcine IL-6, rrIL-6, rmIL-11, rmLIF, or rmOncostatin M is observed. |
| 使用方法 | Neutralization: Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. The Neutralization Dose (ND50) is typically 10-30 µg/mL in the presence of 50 ng/mL Recombinant Canine IL‑6. |
| 来源 | Monoclonal Mouse IgG2A Clone # 247017 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 100034196 (Equine); 493687 (Feline); 100008733 (Rabbit) |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | E. coli-derived recombinant canine IL‑6 Thr23-Met207 Accession # P41323 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Canine |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature canine IL-6 is 187 amino acids (aa) in length and shares 76%, 59%, 38%, and 40% aa sequence identity with feline, human, mouse, and rat IL-6, respectively (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130‑expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL‑6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Proliferation Induced by IL‑6 and Neutralization by Canine IL‑6 Antibody. Recombinant Canine IL‑6 (Catalog # 1609-CL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Canine IL‑6 (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Canine IL‑6 Monoclonal Antibody (Catalog # MAB1609). The ND50 is typically 10-30 µg/mL. |
